Phase II Study of Induction Erlotinib Therapy in Stage III A(N2) Non-small Cell Lung Cancer Proceeding to Mediastinoscopy/PET and Thoracotomy/Radiotherapy

Trial Profile

Phase II Study of Induction Erlotinib Therapy in Stage III A(N2) Non-small Cell Lung Cancer Proceeding to Mediastinoscopy/PET and Thoracotomy/Radiotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jun 2010 To date, 13 patients have been enrolled, according to a poster presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO).
    • 13 Jan 2010 Planned end date changed from 1 Sep 2010 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top